Bence Jones Proteins Bind to a Common Peptide Segment of Tamm-Horsfall Glycoprotein to Promote Heterotypic Aggregation

Zhi-Qiang Huang, Katherine A. Kirk, Kevin G. Connelly, and Paul W. Sanders
Nephrology Research and Training Center, Division of Nephrology, Departments of Medicine, Physiology, and Biostatistics and Biomathematics, University of Alabama at Birmingham, and Veterans Affairs Medical Center, Birmingham, Alabama 35292

Abstract

Bence Jones proteins (BJPs) are the major pathogenic factor causing cast nephropathy ("myeloma kidney") by coaggregation with Tamm-Horsfall glycoprotein (THP). Understanding the interaction between these proteins is therefore important in developing treatment strategies to prevent renal failure from cast formation in multiple myeloma. We developed an enzyme-linked immunoassay to examine this phenomenon. Five different human BJPs (four κ and one λ immunoglobulin light chains) were used in this assay that demonstrated these proteins bound THP with different affinity. BJPs competed among themselves for binding to THP. The binding site was a peptide portion of THP since these proteins also bound deglycosylated THP. Also, a monoclonal antibody directed against a peptide segment of human THP prevented binding of THP to BJPs. By altering the conformation of THP, reducing agents decreased binding between these two proteins in concentration-dependent fashion. In turbidity studies, the monoclonal antibody that prevented binding and a reducing agent, dithiothreitol, decreased coaggregation. Deglycosylated THP did not coaggregate with BJPs. We concluded that ionic interaction between BJPs and a specific peptide binding site on THP promoted heterotypic coaggregation. The carbohydrate moiety of THP was also essential for coaggregation, perhaps by facilitating homotypic aggregation of THP. (J. Clin. Invest. 1993. 92:2975–2983.) Key words: renal failure • Bence Jones proteins • Tamm-Horsfall glycoprotein • reducing agents • multiple myeloma

Introduction

About half of patients presenting with multiple myeloma have concomitant renal insufficiency usually related to Bence Jones proteinuria (1–3). While a variety of renal lesions are associated with multiple myeloma (4), cast nephropathy, or "myeloma kidney," is perhaps best recognized and most common (5, 6). Using micropuncture techniques, Oliver (7) demonstrated large numbers of casts obstructing tubule lumens of patients who died from myeloma and renal failure, hence the term cast nephropathy. These intraluminal casts are composed of Bence Jones protein (BJP)1 and Tamm-Horsfall glycoprotein (THP) (8), a protein that is synthesized by cells of the thick ascending limb of the loop of Henle (9, 10) and is the major constituent of urinary casts (11). As shown originally by Koss et al. (12) and confirmed by others (13–19), cast nephropathy can be reproduced in mice and rats by parenteral injection of purified human Bence Jones protein. We have demonstrated that cast-forming human Bence Jones proteins coaggregate with Tamm-Horsfall glycoprotein to obstruct the distal nephron (14–16). In addition, intravenous infusion of nephrotoxic human Bence Jones protein in rats elevates proximal tubule pressure and simultaneously decreases single nephron glomerular filtration rate; intraluminal protein casts were identified in these kidneys (18). Thus, intraluminal obstruction from cast formation appears to be a prominent cause of acute renal failure in multiple myeloma. Because of the central role of Bence Jones proteins and Tamm-Horsfall glycoprotein in renal failure from cast nephropathy, our current study examines in detail the binding interaction between these proteins. Characterization of this interaction allows development of new therapies that focus specifically on this basic pathogenic mechanism of cast nephropathy and may serve to decrease morbidity and mortality from renal failure in multiple myeloma.

Methods

Protein preparation. Five different BJPs were used in these studies. BJPκκ, BJPκλ, and BJPλλ were purified from the urine of patients who had multiple myeloma and renal failure using techniques described previously (20). These proteins corresponded to those proteins (previously referred to as BJP1, BJP2, and BJP3, respectively) used in previous studies (14, 15). Because of the relative abundance of these proteins and the requirement of large amounts of protein in some experiments, these three BJPs were used in the majority of studies. BJPκκ was from a patient who had no clinical evidence of renal dysfunction, although under conditions of mild depletion of extracellular fluid volume, this protein obstructed the rat distal nephron (16). BJPκλ was from a patient who had renal failure and histopathologic evidence of cast nephropathy. These two proteins were generous gifts from Dr. Alan Solomon (University of Tennessee Medical Center, Knoxville, TN). All BJPs except BJPκκ were kappa light chains. THP was purified from the urine of a normal male volunteer in standard fashion (15) by precipitation with NaCl, 0.64 M, followed by centrifugation at 48,000 g for 15 min. The pellet was resuspended with deionized water, then dialyzed against deionized water for 72 h. The protein was lyophilized and stored at −20°C. Electrophoresis of this product using a 7.5% polyacrylamide gel (SDS-PAGE) demonstrated a single band at ~ 100 kD.

1. Abbreviations used in this paper: BJP, Bence Jones protein; THP, Tamm-Horsfall glycoprotein.
Western blotting using rabbit polyclonal antiserum against human TPH (Biomedical Technologies Inc., Stoughton, MA) confirmed the identity of this band as TPH.

Several experiments used deglycosylated TPH, which was prepared by dissolving TPH, 10 mg/ml, in 1% SDS (Bio-Rad Laboratories, Richmond, CA), boiling for 5 min, then mixing in sodium phosphate buffer, pH 8.6, containing 160 mM sodium phosphate, 5 mM 1, 10-phenanthroline, 0.3% Triton X-100, and 100 U/ml N-glycosidase F (PNGase F; Boehringer Mannheim Biochemical, Indianapolis, IN). The final concentration of TPH was 0.5 mg/ml. The mixture was incubated at 37°C for 18 h. After the incubation, the buffer was changed to 1% Tween 20 in PBS with at least three buffer exchanges using a microconcentrator (Centricon 30; Amicon, W. R. Grace & Co., Beverly, MA). Deglycosylated TPH was then aliquoted and stored at −20°C. Successful deglycosylation of TPH was confirmed using a glycan detection kit (Boehringer Mannheim Biochemical), which detects the presence of carbohydrate with as little as 10 ng of glycoprotein.

A mouse monoclonal antibody against purified human TPH was raised in our laboratory and purified from the medium using ammonium sulfate precipitation and a protein G column (Pharmacia LKB Biotechnology Inc., Piscataway, NJ). To determine whether this monoclonal antibody reacted with the peptide portion of TPH, TPH and deglycosylated TPH underwent electrophoresis (SDS-PAGE) using a 12% polyacrylamide gel. After transfer of these proteins onto nitrocellulose and washing in standard fashion, the membrane was incubated with our mouse anti–human TPH monoclonal antibody, followed by rabbit anti–mouse IgG antibody conjugated with horseradish peroxidase (Bio-Rad, Melville, NY). After additional washes, the membrane was developed using peroxidase substrate (0.1 mM Tris/HCl, pH 7.4, 0.8 mg/ml 3,3′-diaminobenzidine, 0.01% hydrogen peroxide).

**Binding analysis studies.** To characterize the binding of TPH with BJPs, an enzyme-linked immunoassay was developed. In these and subsequent studies that compared binding of the various BJPs to human TPH, all five proteins were examined simultaneously on the same microplate. Wells of microplates were coated with BJPs, 2 μg/ml in PBS, pH 7.4, and incubated overnight at room temperature. The wells were washed three times with 0.05% Tween 20 in PBS. The remaining unoccupied binding sites in the wells were blocked by incubating with 1% BSA in PBS for 1 h at room temperature. Native TPH or deglycosylated TPH, suspended in 1% Tween 20 in PBS, was added to the wells (100 μl/well) after additional washes with 0.05% Tween 20 in PBS. The microplates were incubated for 30 min at room temperature. Polyclonal rabbit antibody against human TPH, 1:3,000 dilution in PBS, was added to the wells, followed by horseradish peroxidase-conjugated goat anti–rabbit IgG antibody (Bio-Rad, Melville, New York), 1:1,000 dilution in PBS. Microplates were incubated with each of the antibodies for 1.5 h at room temperature followed at the end of each incubation by three washes with 0.05% Tween 20 in PBS. Wells were developed using azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma Chemical Co., St. Louis, MO), 2.5 mg/ml, in citrate-phosphate buffer, pH 4.2. Optical density was determined at 405 nm using a microplate reader (THERMOmax; Molecular Devices Corp., Menlo Park, CA).

Binding curves were constructed for each of the five BJPs by varying the amount of TPH in the incubating solution between 1 and 1,000 μg/ml. In other experiments, to examine the effect of duration of exposure on binding of TPH to BJPs, TPH, 150 μg/ml, was incubated with each of the five BJPs for 0–60 min. TPH bound to BJPs in the wells was determined as described above.

In other studies, all five BJPs were biotinylated in standard fashion (21), using sulfo-N-hydroxysuccinimidobiotin (ImmunoPure Sulfo-NHS-Biotin; Pierce Chemical Co., Rockford, IL), followed by dialysis against PBS at 4°C for 24 h to remove free biotin. The relative amount of biotinylolation per mg BMP was determined as follows. All five biotinylated proteins, 100 μg/ml, were blotted simultaneously onto nitrocellulose membrane, which was then incubated 30 min in 1% BSA-containing 4% BSA. After washing three times with 0.05% Tween 20 in PBS, the membrane was incubated in PBS that contained 1% BSA and streptavidin-conjugated horseradish peroxidase (Southern Biotechnology Associates, Inc., Birmingham, AL), 1:1,000 dilution. The membrane was developed using peroxidase substrate (0.1 mM Tris/HCl, pH 7.4, 0.8 mg/ml 3,3′-diaminobenzidine, 0.01% hydrogen peroxide). The color reactions of each dot blot were quantitated using a densitometer (model 620 video densitometer; Bio-Rad Laboratories, Richmond, CA) and were used to determine the relative ratios of biotinylination among the five proteins. These correction factors for biotinylination were used in subsequent studies that used these biotinylated proteins. To quantify binding of each of the BJPs to wells of microplates, initially 1 part biotinylated BMP was mixed with 14 parts unbiotinylated BMP in PBS to produce a final protein concentration of 2 μg/ml. Wells of microplates were then incubated with each BMP solution overnight at room temperature. After blocking with 1% BSA in PBS and washing with 0.05% Tween 20 in PBS, streptavidin-conjugated horseradish peroxidase, 1:3,000 dilution in PBS, was added to the wells, followed by peroxidase substrate. Optical density was determined at 405 nm using a microplate reader (THERMOmax; Molecular Devices Corporation).

In a separate experiment, wells of microplates were coated with TPH, 2 μg/ml, overnight at room temperature. After blocking and washing, each biotinylated BMP, 0–300 μg/ml, was added to the wells, which were incubated for 30 min at room temperature. After extensive washes, streptavidin-conjugated horseradish peroxidase, 1:3,000 dilution in PBS, was added to the wells, followed by peroxidase substrate. Optical density was determined at 405 nm using a microplate reader (THERMOmax; Molecular Devices Corporation).

**Effects of reducing agents.** To define further the binding interaction between BMP and TPH, we included reducing agents in our binding assay. After coating wells of microplates with a test BMP and washing and blocking as described above, 50 μl β-mercaptoethanol, 250 mM, was added to the wells, followed by 50 μl TPH, 300 μg/ml. The plate was shaken once and incubated for 30 min at room temperature. Other reducing agents, including cysteamine, penicillamine, dithiothreitol, L-cysteine, and N-acetyl-L-cysteine were also tested in this fashion in doses between 0 and 300 mM using BMPsub, BMPsup, and BMPant. Two closely related compounds, cysteamine and cystamine-S-phosphate, 0–300 mM, were used as controls because they did not possess free sulfhydryl groups and therefore did not serve as reducing agents. In a separate experiment, after incubating wells that contained the five BJPs with TPH for 30 min at room temperature, β-mercaptoethanol, 250 mM, was added after washing, and wells were incubated another 10 min. After extensive washing, TPH bound on the wells was detected as described above. The amount of reducing agent required to inhibit binding of TPH by 50% (ED50) was calculated from these data.

To observe whether BMP and TPH possessed free sulfhydryl groups through which binding may have occurred, 20 μl of BMPmic, BMPsup, BMPant, and TPH, 1 mM in PBS, pH 7.4, were mixed with 100 μl 5,5'-dithiobis(2-nitrobenzoic acid) (Ellman's reagent; Cayman Chemical Co., Inc., Ann Arbor, MI) in a microplate and incubated for 30 min at room temperature. N-Acetyl-L-cysteine was used as a positive control. Optical density was read at 405 nm using a microplate reader. In a separate experiment, BMPant, 1 mg/ml, was incubated with 1 mM and 10 mM iodoacetamide, a potent thiol-blocking agent. These treated BMPant preparations were diluted to 2 μg/ml and used to coat the wells of microplates. Binding assay was performed as described above and compared to binding reaction between TPH and untreated BMPant.

To examine whether reducing agents affected directly either BMP or TPH, wells of microplates were coated with BMPsub, BMPsup, BMPant, and TPH, 2 μg/ml, and were washed and blocked as described. Dithiothreitol, 0–100 mM, was added to the wells and incubated for 30 min at room temperature. After extensive washing with 0.05% Tween 20 in PBS, TPH, 150 μg/ml, was added to the wells coated with BJPs, followed by rabbit anti–human TPH and goat anti–rabbit IgG antibody conjugated with horseradish peroxidase. BMPsub, BMPsup, and BMPant, 1 mg/ml, were added to the wells coated with TPH followed by goat antikappa THP, streptavidin–Lambdachain antibodies (Orygonon Teknika, West Chester, PA) and rabbit anti–goat IgG antibody conjugated with horseradish peroxidase (Bio-Rad, Melville, NY). The plates were
washed again and developed using the same substrate. Optical density was read at 405 nm.

**Competition studies.** To determine whether different BJPs bound to the same site on THP, wells of microplates were coated with the five BJPs, 2 μg/ml in PBS, and incubated overnight at room temperature. After washing with 0.05% Tween 20 in PBS and blocking with 1% BSA in PBS for 30 min, 50 μl of BSA or BJPmic, BJPr, and BJPdon, 0.02-60 mg/ml, was added to the wells, followed by 50 μl THP, 300 μg/ml. The plates were shaken to mix THP and BJPs thoroughly and incubated for 30 min at room temperature. After extensive washing, THP bound to wells was determined as described above.

In other experiments, our mouse monoclonal anti-human THP antibody, 0.1-33 μg/ml, was used as a competitor in this binding assay. Another commercial mouse monoclonal anti-human THP antibody was purified from mouse ascitic fluid (Accurate Chem. & Sci. Corp., Westbury, NY) using 50% ammonium sulfate precipitation and a THP-conjugated Sepharose 4B (Sigma Chemical Co.) affinity column. Final antibody concentration was adjusted to 33 μg/ml before use. BSA served as a control in these experiments.

Finally, because human THP contains an RGD (arginine-glycine-aspartic acid) peptide sequence (10, 22) which is a common binding site for adhesion molecules (23), we used a synthesized RGD peptide (Bachem Bioscience, Torrance, CA), 0.0075-2.5 mg/ml, as a competitor in these studies.

**Turbidity measurements.** As described previously (15, 16), to observe coaggregation of THP with BJPs in vitro, turbidity of solutions containing THP and deglycosylated THP, 0.125 μg/ml in PBS, pH 7.4, was determined using a spectrophotometer (M-series; Photon Technology International, Inc., South Brunswick, NJ) at an excitation and monitoring wavelength of 488 nm. After confirming a stable baseline, change in turbidity was determined after adding BJPmic, BJPr, and BJPdon, 0.06 mg/ml. These concentrations of proteins were used because they reflected the relative amounts and ratios of these proteins found in the distal nephron. Furthermore, they were identical to those used previously (16). These protein ratios differed from those used in the initial binding analysis studies but were similar to those experiments that used biotinylated BJPs. In other studies, THP was preincubated with our monoclonal anti-human THP antibody, 3.5 μg/ml, and change in turbidity after addition of BJS was monitored. To observe the effect of reducing agents on the coaggregation, changes in turbidity of THP-containing solutions were monitored after addition of dithiothreitol, 1.5 mM.

**Statistical analysis.** Two statistical models were used to estimate parameters of interest in the binding analysis studies. The first was a two-parameter, cumulative negative exponential with the parameters being a maximum response and either an initial slope or the EC50, as desired. The second was a logistic model in which the logarithm of the concentration was the independent variable. This second model can be rearranged to handle both increasing and decreasing responses. The parameters for the logistic were a maximum response, the log (EC50) or the EC50, and the slope at log (EC50). In a few cases, a nonzero minimum response was also required. Estimation was performed using the multivariate secant algorithm (DUD), a derivative-free method available in the nonlinear least squares procedure (NLIN) of the Statistical Analysis System (SAS Institute, Inc., Cary, NC). This method produces estimated standard errors for the parameter estimates and 95% confidence interval estimates of the parameters. The two-parameter model appeared to be adequate to describe the association curves; dose response and competition curves more often required the logistic.

**Results**

**Binding analyses.** All five BJPs bound THP; these interactions displayed saturation kinetics (Figs. 1 and 2). These BJPs presented varying binding affinities and initial binding rates to THP (Table 1). BJPmic and BJPrhymost avidly, while BJPr and BJPrehad the lowest affinities (Figs. 1 and 2). Using biotinylated BJPs, binding of the BJPs to wells of microplates did not differ (Fig. 3). Therefore, efficiency of coating wells of microplates was not a variable in these and subsequent studies that used microplates coated initially with BJS. Experiments that examined binding of biotinylated BJPs to THP-coated wells also showed results comparable to the initial binding studies, with BJPrhymic, and BJPdon, demonstrating high binding affinities for THP, and BJPr and BJPrelow affinities.

![Figure 1. Effect of increasing concentrations of THP on binding to BJPs (n = 5 experiments). In these experiments, the wells had been coated with the test BJS, 2 μg/ml, and THP, 0-1,000 μg/ml, was added subsequently. Data from each experiment were standardized by making the maximum optical density for each experiment equal to 100%. As indicated by the initial slopes of the curves, the affinities of BJPs to THP varied. BJPr and BJPrehad the highest affinities to THP, while BJPr and BJS had the lowest (Table 1).](image)

![Figure 2. Time course of THP binding to BJPs (n = 5 experiments). A constant amount of THP, 150 μg/ml, was added to wells coated with BJS, 2 μg/ml. Data from each experiment were standardized by making the maximum optical density for each experiment equal to 100%. Initial binding rates of these proteins to THP differed and are shown in Table I. Again, BJPr and BJPrhymost avidly, while BJPr and BJPrehad the lowest initial slopes, BJPr and BJPrehad the lowest.](image)
Table I. Half-maximal Binding Concentration (EC₅₀) and Initial Binding Rates of THP with Each of the Five BJPs

<table>
<thead>
<tr>
<th>Protein</th>
<th>BJPrhy</th>
<th>B Jenner</th>
<th>B Jenner</th>
<th>BJPray</th>
<th>BJPen</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC₅₀, µM</td>
<td>8.9±0.5</td>
<td>13.8±2.3</td>
<td>17.9±2.2</td>
<td>144.5±24.9</td>
<td>363.0±19.1</td>
</tr>
<tr>
<td>Initial binding rate, % bound per min</td>
<td>36.3±2.5</td>
<td>21.6±3.1</td>
<td>11.1±1.2</td>
<td>1.7±0.2</td>
<td>0.2±0.0</td>
</tr>
</tbody>
</table>

(data not shown). Deglycosylated THP also bound to all five BJPs in a fashion similar to native THP (Fig. 4).

Reducing agents inhibited binding of THP to BJPs in a dose-dependent fashion. Dithiothreitol was the most potent inhibitor (Table II). Cystamine and cysteamine-S-phosphate, two compounds that did not contain free sulfhydryl groups, had no effect on the binding of THP to BJPs. Similarly, β-mercaptoethanol decreased binding of THP to BJPs (Fig. 5). After THP bound to BJPs, incubating with this reducing agent also removed bound THP (Fig. 5). Using Ellman’s reagent, free sulfhydryl groups on BJPmic, BJPrap, BJPdon, and THP were not detected. When BJPmic, BJPrap, and BJPdon coated on the wells of microplates were pretreated with dithiothreitol, which was removed before addition of THP, binding of THP was not influenced. In contrast, when THP coated on the wells of microplates was pretreated with dithiothreitol before addition of BJPs, binding of BJPmic, BJPrap, and BJPdon decreased with increasing doses of dithiothreitol. In these studies, the amount of dithiothreitol required to inhibit the binding of THP by 50% (ED₅₀) was 0.07 mM for BJPmic, 0.7 mM for BJPrap, and 0.7 mM for BJPdon.

**Competition studies.** BJPmic, BJPrap, and BJPdon competed with all five BJPs for binding to THP coated on wells of microplates (Fig. 6). Competition occurred in a dose-dependent fashion. Among the different proteins, competition depended upon the binding affinities of the individual BJP. BJPmic and BJPdon had higher affinities for THP and served as stronger competitors than BJPrap, which had a low affinity for THP. BSA did not inhibit binding of THP to BJPs. When a mouse monoclonal antibody directed against human THP was used as a competitor, binding between BJPs and THP was inhibited in a dose-dependent manner (Fig. 7). This monoclonal antibody reacted with an epitope on the peptide portion of human THP (Fig. 8). BSA, a commercial monoclonal anti-THP antibody, and the RGD peptide did not decrease binding of THP to BJPs.

**Turbidity measurements.** BJPmic, BJPrap, and BJPdon increased turbidity of solutions containing THP. Hairlike particles in these solutions were seen with the naked eye at the end of these tests. In contrast, turbidity did not increase when the BJPs were added to solutions containing deglycosylated THP (Fig. 9). When our monoclonal anti-human THP antibody was preincubated with THP, the increase in turbidity that occurred with BJPmic, BJPrap, and BJPdon was lessened by 40% (Fig. 10) (n = 4 experiments for each protein). The simultaneous addition of dithiothreitol with BJP to THP-containing solutions reduced the incremental increase in turbidity by 40% (Fig. 11) (n = 4 experiments). Pretreatment of THP with dithiothreitol, 1.5 mM, further reduced subsequent coaggregation with BJP by ~ 80%.

**Discussion**

By coaggregating with THP in the lumen of the distal nephron, BJPs are the principle pathogenic factor in cast nephropathy, or myeloma kidney (15, 16). The current studies were de-

![Figure 3](image)

**Figure 3.** To determine whether binding of the five BJPs to microplate wells differed, solutions containing biotinylated and unbiotinylated BJPs, in a final concentration of 2 µg/ml in PBS, were used to coat wells (n = 12 for each BNP), which were incubated overnight. After washing and blocking, the wells were developed using streptavidin-conjugated horseradish peroxidase and peroxidase substrate. Optical density, which was corrected for degree of biotinylation of each protein (see Methods), did not differ (P = 0.1277) among the five proteins.

![Figure 4](image)

**Figure 4.** Binding of either THP or deglycosylated THP, 150 µg/ml, to microwells coated with BNP, 2 µg/ml. Binding affinities between THP and deglycosylated THP did not differ (n = 3 experiments for each group).
signed to examine the binding interaction between these proteins. Using an enzyme-linked immunoassay, we found that BJPs bound human THP with different affinities. BJPs competed among each other for binding to THP. A monoclonal antibody directed against a peptide portion of THP served as a competitive inhibitor of binding (Fig. 7). BJPs also bound THP that had been completely deglycosylated enzymatically. These data demonstrated that BJPs bound to a common peptide segment on THP. Reducing agents interacted with THP to prevent subsequent binding to BJPs. In agreement with others (24), Ellman's reagent did not detect free thiol groups on THP, suggesting that the binding interaction between these proteins was not covalent. In turbidity studies, both the monoclonal antibody, which prevented binding of BJP to THP, and the reducing agent, dithiothreitol, decreased heterotypic aggregation. Although deglycosylated THP bound to BJPs, coaggregation with BJPs did not occur. In summary, these combined data demonstrated that BJPs bound through ionic interaction to a common peptide region on THP. This heterotypic aggregation was dependent on this interaction as well as the carbohydrate moiety of THP.

THP is composed of 616 amino acids and has eight potential asparagine-linked glycosylation sites (9, 10, 22). Intramolecular disulfide bonds formed between 48 cysteine residues interspersed throughout the molecule are important in keeping a rigid structure; reducing agents do not dissociate the molecule into smaller subunits (9, 22, 24). The major secondary structure is a β-sheet with a regular zig-zag appearance (9, 25). The carbohydrate component accounts for 30% of the total molecular weight and is responsible for homotypic aggregation which promotes gel formation (9, 25). In the present study, the carbohydrate moiety of THP did not influence the binding efficiency to BJPs, which also bound to deglycosylated THP. Thus, unlike other proteins, such as interleukin-1, which binds to the carbohydrate moiety of THP (10, 26), our data demonstrated that BJP was not a lectinlike protein. Previous work found that colchicine, which decreased carbohydrate content of THP (mainly sialic acid), prevented coaggregation of THP with BJP (16). In our present study, complete deglycosylation of THP also abolished coaggregation. Thus, the carbohydrate moiety was essential in heterotypic aggregation of THP and BJP by allowing simultaneously homotypic aggregation among the molecules of THP (9, 25). Possibly, the binding of BJP to THP also changed the net electric charge on the surface of THP to

Table II. Effect of Reducing Agents on Prevention of Binding of THP to BJPs

<table>
<thead>
<tr>
<th>Reducing agent</th>
<th>Chemical formula</th>
<th>Low (ED$_{50}$)</th>
<th>Medium (ED$_{50}$)</th>
<th>High (ED$_{50}$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cysteamine</td>
<td>CH$_2$OH-CH$_2$-NH$_2$</td>
<td>22.7±1.8</td>
<td>32.5±53.1</td>
<td>2.8±0.6</td>
</tr>
<tr>
<td>Penicillamine</td>
<td>CH$_3$-OH-CH$_2$-COOH</td>
<td>54.2±1.1</td>
<td>0.2±0.1</td>
<td>2.8±0.9</td>
</tr>
<tr>
<td>Dithiothreitol</td>
<td>CH$_2$CHCHCH$_2$-SH</td>
<td>2.4±0.1</td>
<td>4.3±3.6</td>
<td>0.7±2.4</td>
</tr>
<tr>
<td>Cysteine</td>
<td>CH$_2$CHCOOH</td>
<td>17.8±1.1</td>
<td>26.3±7.2</td>
<td>7.7±2.4</td>
</tr>
<tr>
<td>N-acetyl-cysteine</td>
<td>CH$_2$CHCOOH</td>
<td>57.9±5.3</td>
<td>8.9±1.3</td>
<td>36.0±12.4</td>
</tr>
<tr>
<td>Cystamine</td>
<td>CH$_2$CH$_2$NH$_2$</td>
<td>No effect</td>
<td>No effect</td>
<td>No effect</td>
</tr>
<tr>
<td>Cysteamine-S-phosphate</td>
<td>PO$_4$-S-CH$_2$CH$_2$NH$_2$</td>
<td>No effect</td>
<td>No effect</td>
<td>No effect</td>
</tr>
</tbody>
</table>

Figure 5. Effect of β-mercaptoethanol on binding between THP and BJPs (n = 3 experiments). In the control groups, THP was added to the wells without β-mercaptoethanol and incubated for 30 min. (A) THP, 150 µg/ml, was added simultaneously with β-mercaptoethanol, 250 mM, to wells coated with BJPs, 2 µg/ml in PBS, and incubated for 30 min. A marked decrease in binding occurred. (B) THP, 150 µg/ml, was added to wells coated with BJP, 2 µg/ml. After 30 min, the wells were washed, then β-mercaptoethanol, 250 mM, was added for 10 min before the plate was washed and developed the plate. β-Mercaptoethanol dissociated the THP–BJP complexes.
favor coaggregation and subsequent precipitation of the THP-
BJP complex.

BJPs represent a family of low molecular weight proteins
that are structurally homogeneous, but unique, immunoglobulin
light chains (27). As suggested originally by Osserman
(28), nephrotoxic potential of BJPs appears to relate to certain
physicochemical characteristics of these proteins. However,
discerning which property(ies) is important has proved diffi-
cult. In the current study, all tested BJPs bound THP, but with
differing affinities, which presumably was related to distinct
physicochemical properties of the BJPs. In the competition
study with BJPs, different BJPs replaced each other despite
having different isotypes (κ or λ). Other investigators showed
that both κ and λ BJPs deposited as casts in mouse and rat
kidneys (13–19, 29). The difference in the binding affinity in the
current study was also not related directly to the isoelectric
point of BJPs (Table III). For example, two BJPs (BJPmic and
BJPdon) that had a similar range of isoelectric points had totally
different affinities to THP. In general, however, isoelectric
point has been found to be an important determinant of coag-
gregation because proteins with isoelectric points < 5.1 did not
aggregate with THP (15), and cationic BJPs were more
nephrotoxic than those BJPs that had lower isoelectric points
(13). These data were further supported in a clinical study,
which found that those patients that excreted BJPs with iso-
electric points > 6.0 had more severe and irreversible renal failure
than those patients that excreted more anionic proteins (30).
The different affinities to THP may relate to amino acid substi-
tutions in the hypervariable peptide segment, which differenti-
tiates those molecules that have highly conserved three-dimen-
sional structures (31). This study did not determine that prop-
erty or peptide sequence responsible for nephrotoxicity, but
has provided a means to study further protein nephrotoxicity;
defining these nephrotoxic properties is a future direction of
this laboratory.

The primary cause of cast formation in myeloma kidney is
filtered BJP from the blood stream (12–19). In a previous
study, we showed that BJPmic, BJPrp, and BJPdon aggregated
with THP in vitro. BJPmic was most potent in causing aggrega-
tion, while BJPrp was the weakest (15). These data were con-
sistent with the binding affinities of these three BJPs to THP in
the current study (Figs. 1 and 2). Thus, binding affinity was
closely related to heterotypic aggregation. Because the binding
affinity of BJP to THP correlated with aggregation, this char-
acteristic of BJP appeared to be a basic criterion for cast for-
formation. While binding of BJP to THP may be considered a risk
factor promoting cast nephropathy in patients with multiple
myeloma and Bence Jones proteinuria, more studies are re-

Figure 6. Results of competition study using
BJPmic (κ light chain), BJPrp (κ light chain), and BJPdon (λ light chain) (n = 3
experiments). The BJP used to coat the
wells is shown at the top of each graph. All
three BJPs competed among each other
and with the other two BJPs for binding to
THP. BJPmic and BJPdon possessed the
highest affinities for THP and were the
strongest competitors.

Figure 7. Results of competition study using
a mouse monoclonal anti-human THP
antibody (mAb) (n = 3 experiments). All
five BJPs were used in this study. To wells
coated with the test BJP, 2 μg/ml in PBS,
THP, 18.75 μg/ml, was added simulta-
neously with either BSA or mAb, 0.1–33
μg/ml. Because of the low affinity of BJPrp
and BJPdon for THP, THP, 150 μg/ml, was
added simultaneously with antibody to
wells coated with these two BJPs. This
monoclonal antibody blocked binding of
THP to every BJP in a dose-dependent
manner.
required before the kinetics of binding determined by ELISA may be used as a clinical tool. Cast formation is also related to other factors, such as pH and ion concentrations in the distal tubular fluid, extracellular fluid volume, use of loop diuretics, hypercalcemia, and concentrations of BJP and THP in the thick ascending limb of the loop of Henle (2, 14–16, 29, 32–34). For example, BJP_{im} was obtained from a patient who had no clinical evidence of cast nephropathy. This BJP did show low binding affinity to THP in our present study. In our tubular microperfusion study, BJP_{im} did not obstruct the distal nephron of euvoletic rats. However, obstruction from cast formation in the distal nephron occurred when mild extracellular fluid depletion was created (16). In contrast, euvoletia slowed, but did not prevent, intraneplhal obstruction from

**Figure 8.** Analysis of THP and deglycosylated THP (DGTHP). SDS-PAGE of THP (lane 1) and deglycosylated THP (lane 2) after staining of the gel with Coomassie blue demonstrated the molecular weight of deglycosylated THP decreased to ~ 66. The middle panel was a Western blot of THP (lane 1) and deglycosylated THP (lane 2), using our monoclonal antibody against human THP. This antibody recognized both native THP and deglycosylated THP and thus reacted to a peptide segment of THP. A smaller band was consistently observed below the deglycosylated THP on the Western blot, but the amount of this protein that was present was too low to be seen using Coomassie blue (first panel, lane 2). The second band of lower molecular weight identified by the monoclonal antibody was probably due to partial proteolysis of THP occurring during the enzymatic deglycosylation process. Glycoconjugate analysis was accomplished using a glycan detection kit. Carbohydrate was not detected on deglycosylated THP (DGTHP) (third panel, lane 2).

**Figure 9.** Change in turbidity of solutions containing THP and deglycosylated THP after addition of BJPs (n = 3 experiments). Turbidity increased when BJP_{im} was added to the solution containing THP. No apparent incremental increase in turbidity was seen when BJP_{mic} was added to the solution containing deglycosylated THP.

**Figure 10.** Change in turbidity of solutions containing THP and BJPs in the presence or absence of our monoclonal antibody against human THP. Initial slopes of the aggregation curves were calculated to represent the abilities of BJPs to aggregate THP and were illustrated in parentheses. All three BJPs coaggregated with THP. This effect was partially blocked when the THP solution was preincubated with monoclonal antibody.
BJPmic, which had a higher binding affinity for THP. Thus, other factors were also important in modulating BJP–THP aggregation to produce intraluminal obstruction from cast formation. In the management of multiple myeloma, a combined consideration of all these factors should be applied to prevent renal failure.

In summary, we identified a binding site for BJP on the peptide portion of THP. Taken together with previous studies (15, 16), in the proper setting binding to THP resulted in aggregation that ultimately produced distal nephron casts that obstructed the tubule lumen. Previously, we demonstrated that colchicine modified this binding interaction to prevent cast formation in rats (16). In the present study, reducing agents, by breaking the abundant intramolecular disulfide bonds and thus changing the tertiary conformation of THP, decreased binding and subsequent coaggregation of this protein with BJPs. Cysteaminine and N-acetyl cysteine have been used clinically to treat other disorders with minor side effects (35). The possible role of reducing agents, with or without colchicine, to prevent cast nephropathy and potentially dissolve casts once they have formed in myeloma patients requires further studies.

**Table III. Characteristics of BJPs Used in These Studies**

<table>
<thead>
<tr>
<th>Protein</th>
<th>Isotype</th>
<th>Isoelectric point (range)</th>
<th>Nephrotic</th>
<th>Avidity for THP</th>
</tr>
</thead>
<tbody>
<tr>
<td>BJPmy</td>
<td>κ</td>
<td>5.2, 5.3, 5.4* (5.2–6.6)</td>
<td>Yes—documented cast nephropathy</td>
<td>Highest</td>
</tr>
<tr>
<td>BJPmic</td>
<td>κ</td>
<td>7.6–7.7</td>
<td>Yes—unknown morphology</td>
<td>High</td>
</tr>
<tr>
<td>BJPdon</td>
<td>λ</td>
<td>5.6–5.7</td>
<td>Yes—distal nephron cast formation in rats (16)</td>
<td>High</td>
</tr>
<tr>
<td>BPNep</td>
<td>κ</td>
<td>6.9–7.2</td>
<td>Yes—distal nephron cast formation in rats (15)</td>
<td>Low</td>
</tr>
<tr>
<td>Albumin</td>
<td>—</td>
<td>4.8</td>
<td>No</td>
<td>Absent†</td>
</tr>
</tbody>
</table>

* Predominant isoelectric point of the BJP. † While not nephrotic in the human subject and euvoletic rats, this protein did cause cast formation and distal nephron obstruction in hydropenic rats (16). ‡ Demonstrated in this and previous (15, 16) studies.

**Acknowledgments**

The authors thank Dr. J. Claude Bennett and Dr. David G. Warnock for their helpful suggestions and review of this manuscript. We also thank Ms. Melinda McMorris and Mr. Brett Thorn for their technical assistance and the Media Service of the Birmingham Veterans Affairs Medical Center for the photography and illustrations.

This work was supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs.

**References**
